China joins with Philips for biomarker/Dx tests research:
This article was originally published in Clinica
Executive Summary
China's Institute of Health Sciences (IHS) and Royal Philips Electronics signed a memorandum of understanding on August 29 to establish a joint molecular medicine research laboratory. The lab, which will be located at the IHS in Shanghai, will focus on biomarker discovery and the development of next-generation in vitro diagnostic tests, with the aim of developing new solutions for the early diagnosis of disease and for monitoring the effectiveness of subsequent treatment. The IHS is part of the Shanghai Institutes for Biological Sciences (SIBS).
You may also be interested in...
China Biotechs, CDMOs Embrace Uncertain Future, New Options Amid WuXi Woes
The shockwave of WuXi's withdrawal from BIO is ripping through the Chinese contract services sector. While some remain hopeful, others are preparing Plan B.
US FDA’s Anti-Misinformation Campaigns Look Safer After Supreme Court Oral Arguments
FDA’s efforts to tackle misinformation may face fewer legal obstacles moving forward, following oral arguments at the Supreme Court on a case that could have broad ramifications for how the government communicates public health information.
The Dog That Didn’t Bark: ODAC Gives Nod To Three Products Despite Negative FDA Reviews
Oncologic Drugs Advisory Committee was swayed by views of its disease area experts in favorably reporting out Geron’s imetelstat for myelodysplastic syndromes and supplemental applications for the CAR-T products Carvykti and Abecma in earlier lines of multiple myeloma.